Podcast appearances and mentions of journey clinical

In this episode of This is Beacon, part of the #Jointheconversation series, hosts Brooke, Rueben, and Brandon sit down with Licensed Mental Health Counselor JoAnn Streany, whose work spans New York, New Jersey, Florida, Connecticut, and Delaware. JoAnn brings over two decades of experience as a former school counselor and now runs a remote private practice specializing in Integrated Nutrition for Mental Health.She shares how nutrition, movement, and sleep play a foundational role in mental wellness and elaborates on how she supports clients using Ketamine-Assisted Psychotherapy (KAP) in partnership with Journey Clinical. Listeners will learn how KAP differs from traditional talk therapy by targeting healing at both the biological and psychological levels.This episode explores:JoAnn's transition from school counseling to private practiceThe intersection of nutrition, sleep, and movement with mental healthThe science and safety of Ketamine-Assisted Psychotherapy (KAP)What Journey Clinical is and how it partners with providersKAP's psychiatric medication management modelKey FAQs on KAP, including pricing, modalities, and insuranceReal-life applications of KAP in areas like mental health, athletics, and eating disordersThe importance of adaptability in leadership and communicationHow policy, training, and emotional regulation play a role in educational and workplace environmentsWhy modeling contentment and resilience mattersWhether you're a mental health professional, a leader, or someone seeking better self-care, JoAnn offers practical insights and thoughtful strategies that foster understanding, connection, and growth.Timestamps00:00 Introduction and Special Guest JoAnn02:47 JoAnn's Professional Journey and Insights32:34 The Culture of Productivity and Its Impact38:53 Balancing Mental Health and Workplace Expectations40:28 Reevaluating Workplace Priorities42:26 Balancing Professional and Personal Life01:01:39 Addressing Emotional Regulation in Education01:04:09 The Importance of Policies and Training01:17:20 Understanding Skill Deficits and Choices

Today, The Frontier Psychatrists welcomes back my friend Ben Spielberg. He's been a reader for a long time and has contributed to the newsletter in the past. It was on Clinical Trial design, a perennial favorite around these parts.With only light edits, what follows is his work, narrated by me, for the Audio Version.I would invite you to the live class today on working as an out-of-network provider, but it sold out last night, so you'll have to wait for the next one. My prior article on Spravato is available here.The year is 2024. OpenAI has just launched its latest update to ChatGPT, promising more natural and less artificial-sounding language. Donald Trump has won the nomination for President of the United States. Another chain of ketamine clinics has engaged in a corporate reorganization. There is conflict in the Middle East. Are we sure that we're not living Groundhog's Day?I am the founder of Bespoke Treatment, an integrative mental health facility with multiple locations that has at times been referred to as a "ketamine clinic." I have also seen countless so-called "ketamine clinics" sell for pennies on the dollar and go bankrupt seemingly overnight. In this case, Numinus, a company that was publicly traded in Canada and owned a number of psychiatric clinics specializing in ketamine in the US and Canada, has sold its clinics to Stella (a company that has stealthily become one of the larger mental health providers in the country and is the first to bring the awesome SGB treatment to scale). It's not the first time this has happened. It's not the second, nor the third, nor even the fourth time this has happened. But yet, the common consensus is that ketamine clinics are a cheap, easy business with recurring revenue. So, what gives?Figure 1. A reddit user asking anesthesiologists if they should start a ketamine or Botox clinic for easy cash on the side. Does this make you feel gross? Should it?The Ketamine Clinic Model 101The most basic outline for a ketamine clinic is as follows: a provider rents an office space with, on average, five or so exam rooms. They buy equipment for infusions like a pump, catheter, needles, and syringes. They buy some comfortable recliner chairs. They hire a receptionist to answer phones, field patient questions, charge credit cards, and handle medical record requests. They hire a nurse to insert the IV, monitor vital signs, check blood pressure, juggle multiple patients at once, and make sure the ketamine is flowing into patients' veins unencumbered. Two SKUs are typically offered: ketamine infusions for mood, which last approximately 40 minutes, and ketamine infusions for pain, which last for up to 4 hours. Zofran is offered for nausea, and some clinics have fun add-ons like magnesium or NAD. An average mood infusion costs around $400-$500 in a medium cost-of-living area, while mood-infusions can run up to $700 in a higher cost-of-living area. Some clinics offer package discounts if patients buy six or more upfront, which helps with cash flow for the clinic (cash now is better than cash later, of course).A Note on Scope of PracticeThe first wave of ketamine clinics was started mainly by providers who were not mental health specialists. Instead, they were owned by anesthesiologists, ER physicians, and sometimes CRNAs. These providers were especially experienced with ketamine in hospital settings, as well as setting up infusions. Psychiatrists, on the other hand, do not usually order infusions in outpatient settings, and very few had actual hands-on experience with ketamine in practice. That being said, there are a number of variations to the model above: psychiatrist-owned ketamine clinics would often prefer to use intramuscular injections in lieu of infusions, but 2-3 injections would have to be given during a single session for mood and pain sessions were out of the question. Other ways to save costs might include having an EMT do the actual injections (this is highly state-dependent), asking nurses or MAs to work the front desk, or working a full-time regular doctor job. In contrast, your nurses run the actual ketamine services via standing orders, a written document that details routine and emergent instructions for the clinic.Some clinics offer full evaluations prior to rendering treatment, but many offer a simple brief screening on the phone to check for contraindications before scheduling a patient for their first session. The clinics owned by psychiatrists have historically been a bit more thorough in terms of the initial psychiatric evaluations, given that they can actually perform initial psychiatric evaluations within their respective scope of practice. Sometimes clinics may have therapists on-site who can render ketamine assisted therapy (meaning, therapy occurring concurrently) for an additional $100-$300. Otherwise, there is not much decision-making that goes on— other than deciding on medication dosages. Most infusions start off at .5mg/kg of body weight, which is by far the most evidence-based dosage. In practice, most clinics increase dosage every session because even though ketamine is considered to be a weight-based medicine for anesthesia, there is thought to be a “sweet spot” of dosage for everyone, if one can imagine an inverted U shape curved, where the ideal dosage for each patient is at the tippity-top of the inversion. Dosage increases are highly variable depending on the clinic: some have a maximum dosage, some will only increase a certain percentage, and some may even use standardized increments (e.g., only offering dosages in increments of 50mg). A typical series of infusions is 6-8 over 3-4 weeks, followed by boosters as needed.Fool's GoldAt first glance, the business model seems fantastic. As a cash business, there are no AR issues, no third party billing companies to deal with, and no prior authorizations to fight over. Sure, the cost is high, but it's not that high compared to many other healthcare services. Since the benefits fade over time, a ketamine clinic has built-in recurring revenue from patients every week, month, quarter, or year – it's like a subscription business! Ketamine is trendy and sexy; TV shows like White Lotus mention it, and ravers from the 90's recall it with great fondness. Unlike SSRIs and psychotherapy, ketamine works for depression fast. It's amongst the fastest treatments for depression that we have today, and there are a lot of depressed people. It can help someone out of debilitating depression in 40 minutes. It has none of the un-sexy side effects of SSRIs like sexual dysfunction, gastrointestinal discomfort, or uncontrollable sweating. Instead, it has sexy side effects: euphoria, hallucinations, and feelings of unity with the universe. Also, unlike SSRIs, it helps most people who try it. It really is an amazing treatment, and I often feel grateful that my clinic is able to offer it to patients in needFigure 2. Most business-savvy reddit user.Supply and Demand… or SomethingMood disorders disproportionately affect individuals who are of lower socioeconomic status compared to individuals with a lot of disposable income. Of course, wealthier individuals are no more immune to mental health disorders than anyone else, but the main target market that benefits most from ketamine just do not have the means to afford it. They don't have $3,000 to burn on yet another treatment that may or may not work. Often, the patients who could really use a series of ketamine infusions cannot scrounge enough money for a single infusion, let alone a whole series and prn boosters. However, there should be enough depressed people with cash to throw around out there… right?Wait, Isn't That A Horse Tranquilizer?Of course, ketamine clinics can find more patients via marketing and advertising. However, I've found that many medical doctors who see this population, like primary care providers, are not up to date with the research. When I first launched my company, I used to go door-to-door to medical buildings in Santa Monica with cookies to speak with them about advancements in interventional psychiatry. I cannot count the number of times that I was laughed out of each office; referring providers are risk-averse, and the perception of ketamine has traditionally been poor. Medical doctors would exclaim, “Of course people feel better; you're getting them high,” and lament that I was administering a drug thought to be highly addictive. Psychotherapists, who would also be fantastic referral partners, generally refer to psychiatry, but it's less common for them to refer to specific treatments. Nowadays, psychotherapists who are particularly invested in ketamine can sign up with venture-backed companies like Journey Clinical and render their own ketamine-assisted psychotherapy with some prescriber supervision. The issue is that despite the media attention, people with depression don't read innovative health newsletters, nor do they review papers in scientific journals. They rely on information from their psychiatrists, medication management providers, and psychotherapists. If they are not told that this is an option for them, they won't hear about it without ad spend. Oh yeah, and there is a major issue with ad spend: the word ketamine itself is a restricted drug term, and legitimate clinics routinely get banned from Google and Meta for mentioning it, which makes digital advertising more difficult than it would be for any other legitimate service.The Matthew Perry EffectKetamine is very desirable for some patients (unfortunately, sometimes the patients who want it most are frankly the worst candidates for it), but I'd wager that the majority of patients who need it are kind of scared of it. They want to feel good, they want relief from depression and trauma, but it's a weird thing to do a drug that is a horse tranquilizer and also an anesthetic in a reclining chair in a medical office that tricks your brain into feeling like you're dead for a little bit. It's kind of far off from acupuncture and more traditional alternative medicine. There is certainly a non-zero addictive potential that needs to be carefully weighed, it's not a particularly comfortable experience for many patients—especially those with a history of trauma—even if it helps after the experience is over. Additionally, the famous actor from the most famous show in the world, who was deemed to have a cause of death relating to ketamine, isn't exactly helping mass adoption. Overall, this just makes marketing and advertising even more expensive, because a) the majority of referring providers are skeptical, b) patients can't pay for it and c) patients who can pay for it are cautious.Disruptive Business ModelsIn the model I've described above, there are 3 sets of cost centers: rent, staff, and marketing. In some areas of the country, rent may be negligible, and in others, it is quite high. Like an owner-operated restaurant, if a clinic is owned by a company that is not a clinician, they have to find one and pay for one. Venture-backed companies like Mindbloom, Better U, and Joyous have also created entire businesses on the back of the COVID-era controlled substance waivers, whereby they send patients ketamine tablets and/or lozenges directly through the mail. Unlike the clinic model, they don't have rent to pay, and since national marketing campaigns are often cheaper than hyper-local brick and mortar campaigns, they are able to find new patients at lower acquisition costs compared to their clinic counterparts. Some patients do extensive research before treatment and only want to find IV clinics that offer specific dosages, but many are fine with the cheapest ketamine possible, and would prefer to pay as low as $150 for an entire month compared to $3,000.Figure 3. Did you sign up for a discounted ketamine subscription on Black Friday after purchasing a new flat-screen TV?Spravato: Coming In HotJohnson & Johnson's branded esketamine (note the prefix es) is on track to reach coveted “blockbuster status.” While it was FDA approved for Major Depressive Disorder in 2019, it took some time to catch on for a number of reasons including skepticism that the added es only added to pharma pockets and didn't actually work, health insurance companies taking time to decide on what their medical necessity criteria should be, and social isolation due to COVID-19 being a thing. My clinic has become one of the larger Spravato providers in the Los Angeles area, and while we still offer ketamine infusions, our infusion census has decreased by over 70%. The scenario is this: a patient with severe depression comes in to see us, they've heard about ketamine, but they find out that Spravato is covered by insurance for a $20 copay. Maybe ketamine has slightly better efficacy (which, in my opinion, is really just a function of being able to adjust dosage). Still, patients would prefer paying a lot less money to receive almost-the-same benefits.Death By A Thousand SticksThere are a number of other issues with the model that become problematic, especially at scale. Large medical distributors like McKesson and Henry Shein have instituted CYA policies, limiting ketamine sales to licensed anesthesiologists. Medical malpractice carriers alike have followed suit, requesting detailed addendums from providers regarding their ketamine training or flat-out refusing coverage for anyone who isn't an anesthesiologist. Since controlled substance manufacturing is directed by the DEA based on their own predictions, it's not uncommon for ketamine to go on shortage for weeks to months at a time. There are a myriad of problems with the model of point solutions which have been detailed here already, but in short, the old adage rings true: if all you have is a hammer, everything looks like a nail, and if all you have is ketamine, everything looks like a juicy vein. But while ketamine is a highly efficacious treatment, it's not the best treatment for everyone, and patients can become downright dysregulated after ketamine, which a clinic in this model just can't handle adequately at scale. And ultimately, methods to do everything cheaper don't work out that well. For example, putting multiple patients in one room may seem like a good idea, but it is ultimately not conducive to the actual ketamine experience. Any sort of vertical integration also adds an insurmountable amount of complexity, like starting to offer Spravato or TMS, because now they have to start accepting insurance, become in-network, manage billing and AR, and so on. Depending on location and the clinic set-up, they also require specialized providers onsite.Figure 4. Supply chain issues abound.Insurance IssuesSome patients try to be well-informed. They, rightly or otherwise, don't believe everything they hear from their providers, so they call up their health insurance companies and ask. They just call the phone number on the back of the card and ask the representative if ketamine infusions are covered. Undoubtedly, the representative says yes—even though many insurance companies have published guidelines that explicitly deny any coverage for ketamine for a mental health disorder. These patients come in frustrated, distrustful of their providers and reaffirms their belief that ketamine clinics are just cash grabs. Even if one manages to obtain a coveted insurance contract for ketamine, like Ketamine Wellness Centers had with the VA, it kickstarts cashflow and complexity issues that scale should sort out, but ultimately doesn't because of the aforementioned issues above.Overall, it is possible to have a successful ketamine clinic in 2024. Still, it isn't easy due to market conditions, the population served, and the ever-changing landscape of mental health treatment. While many successful clinics exist today, the wheels tend to start to fall off when scaling, where all of a sudden, a clinic's reach has surpassed its captive population. Otherwise, it becomes a series of continual cost-cutting until there is nothing left to cut… save for the business itself.Ben Spielberg is the Founder and Chief Executive Officer of Bespoke Treatment, a comprehensive mental health facility with offices in Los Angeles, CA, and Las Vegas, NV. He is also a PhD Candidate in Cognitive Neuroscience at Maastricht University.For more on psychiatric medications, buy my book Inessential Pharmacology. (amazon link).For pieces by other TFP contributors, follow:Alex Mendelsohn, Michelle Bernabe, RN, @Psych Fox, Carlene MacMillan, MD, David Carreon, M.D., Benjamin Lippmann, DO, Awais Aftab, Courtny Hopen BSN, HNB-BC, CRRN, Leon Macfayden and many others! The Frontier Psychiatrists is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe

Let's celebrate. This is episode 100! My guest is Jonathan Sabbagh, Co-Founder of Journey Clinical and I talk about normalising Ketamine therapy for all, plus why PTSD can fire up your career - until you realize it is harmful to you. Since a few years I am following Jonathan and his wife and Co-Founder Myriam Barthe's great work around the idea to build a strong, decentralized network and offerings for KAP (Ketamine Assisted Psychotherapy) to empower as much therapists as possible to execute the therapy. They did an incredible and successful job to make Ketamine therapy available and build a strong system in collaboration with therapists and doctors.In this episode is talk to Jonathan about: -how PTSD can give you a skyrocketing career, until you realiize your “energy” is trauma in disguise-how we both were very good in PTSD friendly jobs (banking & media) and left them because we realised our own PTSD -how Journey Clinical helps therapists to support their patients with ketamine therapy, (eventually psilocybin) if they are interested in trying and why normal “therapy” needs a strong transformation What Journey Clinical doesJourney Clinical is on a mission to transform the growing mental health crisis by accelerating the mainstream adoption of legal, evidence-based Psychedelic-Assisted Psychotherapy as the standard of care for mental health, starting with Ketamine-Assisted Psychotherapy. They have built a leading platform for Psychedelic-Assisted Psychotherapy in the US. They also recently announce a research collaboration agreement with Compass Pathways to inform the development of a scalable delivery and training model for COMP360 psilocybin treatment. Which means, together with Compass, they work on a future delivery model for psilocybin therapy. INFO@journeyclinical @Jonathansabbaghwww.https://www.journeyclinical.com/. Hosted on Acast. See acast.com/privacy for more information.

Your Skin Treatment Is A Journey | Clinical Grade Skincare & Aesthetic Treatments. A lovely discussion today with the fantastic Amanda of AT Aesthetics. Talking all things skin, machine treatments, how to give your clients product recommendations and how morals & ethics should inform the new industry changes.  https://youtu.be/sP2dJ8bOwxY Follow Amanda and her company AT Aesthetics: Instagram: https://www.instagram.com/amanda_taylor_aesthetics/ Join Faces Consent for FREE: https://www.facesconsent.com  Follow your host: https://www.instagram.com/faceitpod  https://www.instagram.com/jess_messenger

Schlidt is the cofounder and managing partner at Palo Santo, a venture capital fund focused exclusively on the advancement of psychedelic therapies for the treatment of mental health disorders and beyond. Based on his own experience with severe depression as a teenager, Schlidt's goal is to steward the most efficacious psychedelic therapies towards FDA approval so that patients may safely, legally, and affordably access these medicines. He has deployed $25 million into 20 companies including Gilgamesh, Journey Clinical and Sensorium.Show Highlights:-The potential of psychedelics for mental health treatment.-Tim's story leading to investment in psychedelics.-Why to practice safe and supervised use of psychedelics in treatment.-Legal and ethical considerations around the use of psychedelics.-What are challenges in developing psychedelics?-Predicitons for psychedelics in mainstream medicine.-Psychedelics for therapeutic and personal growth.

Paul F. Austin welcomes Sunny Strasburg, LMFT, to discuss utilizing IFS & psychedelic-assisted psychotherapy through the Theradelic Approach. Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-232-sunny-strasburg-lmft/ Sunny discusses her multidisciplinary background and how she came to develop her unique therapeutic approach. She incorporates various modalities such as Internal Family Systems (IFS), Eye Movement Desensitization and Reprocessing (EMDR), and the Gottman Method in her work. Sunny emphasizes the importance of personal psychedelic experience for therapists and the need for ethical and well-trained practitioners in the field. She also shares her vision for the future and the challenges of scaling psychedelic therapy while maintaining integrity and respect for the mystery of the psychedelic experience. Sunny Strasburg discusses the Theradelic Approach, which combines Internal Family Systems therapy and psychedelic-assisted therapy. She explains how working with internal parts can lead to self-compassion and coherence. Sunny also shares her experience facilitating Ketamine Assisted Psychotherapy retreats with IFS founder Dick Schwartz, and how they help leaders in various industries lead with self-energy. The conversation then delves into the importance of ethics in artificial intelligence and the potential impact of psychedelics on the AI space. Sunny reflects on the lessons she has learned from plant medicine and emphasizes the importance of being in service and awe.   Sunny Strasburg, LMFT: Sunny Strasburg, LMFT plays a multifaceted role in the fields of psychology and psychedelic therapy, encompassing education, consultation, authorship, and licensed psychotherapy. Her notable literary achievement, "The Theradelic Approach: Psychedelic Therapy: Perspective, Preparation, and Practice," features a foreword by Dr. Richard Schwartz, the creator of the Internal Family Systems model. Through this work, Mrs. Strasburg distills insights drawn from her experiences as an educator, entrepreneur, and psychotherapist. Sunny's professional journey encompasses proficiency in Internal Family Systems and archetypal psychology, alongside certification in Eye Movement Desensitization and Reprocessing (EMDR). As a graduate of Pacifica Graduate Institute and the California Institute of Integral Studies, Mrs. Strasburg holds additional certifications in Psychedelic Assisted Therapy and Research, with specialized knowledge and training in Ketamine, MDMA, and Psilocybin Assisted Psychotherapies. Sunny is the originator and lead educator of The Theradelic Approach, a model of psychedelic-assisted psychotherapy. Her collaboration with Dr. Richard Schwartz and other prominent figures has led to impactful trainings and immersive retreats. Converging the domains of Ketamine Assisted Psychotherapy (KAP), Internal Family Systems (IFS), and Jungian psychology, Mrs. Strasburg has formulated innovative principles and methodologies that elevate therapeutic practices and the conscientious use of psychedelics within clinical frameworks. Sunny's expertise finds expression in prominent conferences like The Psychedelic Summit 2023, Psychedelic Science 2023, SXSW 2023, and the 2023 Expanded States of Consciousness Worldwide Summit. Moreover, her contributions extend to engagements with the 2021 EMDRIA Worldwide Virtual Conference, and her involvement spans diverse platforms, including The Theradelic Approach training, Three Cups Psychedelics, Journey Clinical, Inbodied Training, EMDRIA UK, and the Boston Trauma Conference.   Highlights: Introduction and background Exploring IFS, EMDR, the Gottman Method, & the Theradelic Approach Addressing gaps in psychedelic therapy training The importance of personal psychedelic experience for therapists Understanding trauma mapping Dosage and frequency in ketamine-assisted therapy Working with internal parts using IFS ketamine-assisted psychotherapy retreats for leaders Psychedelics, AI, and ethics Lessons from plant medicine Being in service and awe Resources and trainings   Links: Sunny's website: https://sunnystrasburgtherapy.com/    Sunny's book, “The Theradelic Approach”: https://thetheradelicapproach.com/ Sunny's retreats: https://www.sunnystrasburgretreats.com/   Episode Sponsors: Joyous microdose ketamine. Book your free consultation today! The Coaching Certification Program by Third Wave's Psychedelic Coaching Institute.

Welcome back to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, we're speaking with Jonathan Sabbagh, founder of Journey Clinical, a digital health tech company pioneering a collaborative care model for psychedelic-assisted therapy.Journey Clinical was founded in 2021 with the mission of creating a decentralized clinic model that would enable licensed therapists to incorporate ketamine-assisted therapy (KAT) into their practice.Jonathan and his co-founder (and wife) Miriam Barthes interviewed 600 therapists before starting Journey Clinical to understand their biggest pain points and challenges.When it came to KAT, a promising treatment for several mental health conditions, the overwhelming response from the therapists they interviewed was that it's difficult to find medical professionals with whom they can collaborate on care. After all, therapists do not prescribe medications, and most physicians do not do therapy.Thus, connecting therapists with partner prescribers was the core need, and with this insight, the Journey Clinical model was born.As many who are well-steeped in the psychedelic field are aware, KAT is a promising modality for stubborn mental health conditions, especially when paired with psychotherapeutic support. However, the majority of ketamine usage for mental health is as a standalone treatment at specialized clinics. What is missing from this brick-and-mortar care delivery environment is supportive wrap-around care.And in my opinion, this is the promise of technology-enabled support for psychedelic therapies.I have been a fan of the Journey Clinical model since I first met Jonathan and Miriam back in 2021. From the outset, it was clear they had a unique insight and mission.In this episode, we discuss:* Leaving a career in finance to study clinical psychology;* The role of psychotherapy in supporting transformational perspectives;* The importance of therapeutic alliance;* The origin story of Journey Clinical and the pivot from a service provider to a health tech company; and* The Ryan Haight Act Online Pharmacy Consumer Protection Act of 2008.I should also note that Beckley Waves is an investor in Journey Clinical.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

In today's podcast, Jonathan Sabbagh, CEO of Journey Clinical, joins Allison to discuss the history of ketamine in mental health settings, the way ketamine works in your brain, plus how ketamine helps integrate insights. Sponsored by: TherapyNotes®: Use promo code Abundant for 2 months free Heard: Use promo code ABUNDANCE  for 1 month free To learn more about today's guest, visit https://www.abundancepracticebuilding.com/blog.  Why put off success? Join the Abundance Party today & get 40% off your 1st month with coupon code BACKTOSCHOOL: https://abundancepracticebuilding.com/abundanceparty

In this Psychedelic Podcast episode, Paul F. Austin welcomes Jonathan Sabbagh, CEO of Journey Clinical, who shares his mission to integrate FDA-approved psychedelics within the modern therapeutic framework. Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-209-jonathan-sabbagh/ Jonathan highlights the disjointed nature of today's mental health system, where therapists and prescribers lack communication, hindering comprehensive assessments and referrals. He and Paul emphasize Journey Clinical's collaborative care model, streamlining information exchange, and maximizing psychedelic-therapy access through telemedicine innovation. They explore Journey's potential challenges of scalability, therapist training, and insurance coverage for extended sessions. And they consider the balance between state-level decriminalization, psychedelic medicalization, and decentralized access. Join Paul and Jonathan as they imagine a new mental healthcare infrastructure that addresses the growing crisis and reinvents therapeutic care as we know it.   Jonathan Sabbagh: Jonathan Sabbagh is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to psychedelic-assisted psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health. During that time, he personally experienced the transformative benefits of plant medicine and ketamine-assisted psychotherapy (KAP). Jonathan's healing journey inspired him to begin formal clinical psychology training at the New School, with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans with depression and anxiety. Jonathan's personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale. Highlights: How Jonathan's mental health & finance background led him to start Journey Clinical. Jonathan's take on co-founding and running Journey Clinical with his wife. The origin story of Journey Clinical and its startup challenges. Exploring Journey's collaborative care model. Investigating Journey's infrastructure solution for psychedelic-assisted therapy. Journey's vetting requirements for network therapists. How the Ryan Haight Act might affect ketamine telehealth access. Journey's decentralized approach to safe and responsible ketamine telemedicine. Integrating FDA-approved psychedelics into the mainstream mental health infrastructure. Jonathan's long-term vision for collaborative mental health care through Journey Clinical. Key Links: Journey Clinical: https://www.journeyclinical.com/ Journey Clinical on Instagram: https://www.instagram.com/journeyclinical Jonathan on Twitter: https://twitter.com/sabbaghjonathan?lang=en Episode Sponsors: Psyched Wellness - use code THIRDWAVE23 to get 15% off. Apollo Neuro - Third Wave listeners get 15% off.

Matias Serebrinsky, the co-founder of Cookunity and PsyMed Ventures, has had an intriguing journey from his birthplace in Argentina to leading two successful ventures in the United States. His experiences as a founder and venture capitalist, coupled with his passion for mental health, have shaped him into a dynamic and innovative leader. his venture, PsyMed Ventures, has funded companies like Freedom Biosciences, Journey Clinical, and Delix Therapeutics.

Union Square Ventures has some of the best performing funds in the venture capital industry. As I've reported, USV-backer UTIMCO disclosed in a recent filing that USV had delivered the public investment fund an internal rate of return of 59%. And that number will likely go up over time. (For instance, USV portfolio company Casetext sold to Thomson Reuters for $650 million after the UTIMCO performance update.) I invited USV managing partner Rebecca Kaden onto the Newcomer podcast to talk about how USV consistently invests in unconventional companies. We started off our conversation talking about Journey Clinical, the psychedelics company, in which Kaden announced a Series A investment in January. We also discussed USV's $200 million climate fund strategy, her interest in the AI application layer, and how rising interest rates are effecting the venture capital asset class. Give it a listenHighlighted ExcerptsThe transcript has been edited for clarity.Eric: How do you repeatedly invest in weird things like psychedelics?Rebecca: This thesis around access to care, which has attracted so much capital — some of it ours and is proving to be a good category — has been where the market has gone, but it's actually only one piece of the puzzle. The way we get into things that are unusual is by having strong theses about where things are going versus being extremely opportunistic. Obviously, there's a balance. But that thesis thinking is important. A lot of thesis work on this category really led to the belief that access to care is only half the puzzle. The other is how is care itself going to evolve, and you start unraveling that thread: how is care itself evolving? The real biggest last evolution of care is SSRIs. Those are prescription drugs and have been very important to the treatment for mental health crises, but there's a lot of things they don't treat. They're not a one size fits all model. And they're basically all we got, right? The innovation has not had a lot of other layers, except for psychedelics. And so we became very interested in psychedelics as the next card to get turned over and the next option in needing a bucket of options to treat a crisis.Eric: There are pharmaceutical companies. If there's money to be made, shouldn't they be trying? What's happening that it feels like you need a real outsider thinking to bring ketamine, a drug that's legal, to people's lives that the medical system is unable or unwilling to do what's happening?Rebecca: Well, this isn't really unique to psychedelics or to mental health. Pharmaceutical companies make drugs, so the development of drugs goes with them, but the distribution and networks of access is outside of it. That's not particularly new or unique here. That's where business opportunity has been. So the idea is, when you talk about distribution and networks of access, that's often where these business opportunities lie. The development of drugs is kind of a different beast, which lies in the pharmaceuticals. Why is there a business opportunity with creating access? Because the same reason technology drives business opportunity into anything. Offline access is slower, it's more gated; it's more piecemeal. You have to be at the right doctor at the right time, you have to find it. By creating a network, you just allow anyone anywhere to find access and education at a faster speed and with much broader supply, which brings efficiency to the market.Eric: Do you think mushrooms are going to be on the table soon? Or how much was this a bet that the regulatory regime would change?Rebecca: I don't think mushrooms as we think about them in a recreational sense are just gonna get legalized, maybe they will, but that's a separate kind of thing. I think other forms of psychedelics in formats that are right for care are very much going to get legalized. And actually, as we did our research, to us that's a when not an if. When you dig into what's going on clinical trials and in the clinical world, in some ways that seems pretty easy to bet on that these will continue to happen. And if not exactly the form that we've outlined, rapid new forms of options for care for mental health diseases are going to get approved and released. They're going to need a network of education and distribution to go into the therapist network.I do think there's a regulatory risk here. There's some amount of regulatory risk on psychedelics. We have to be honest about it. But I actually think more about regulatory risk across broader online healthcare in general. We're at somewhat of a time of that whole market still getting worked out on not unique to mental health and not unique to psychedelics, but what you can prescribe online and to whom and to how and how to allow that really important access that we've come to rely on, but also do it in an appropriately controlled way.Eric: You come from a consumer focused firm. When you were interviewing with USV, was it clear that you were shifting away from consumer, and how have you thought about consumer professionally?Rebecca: We don't think a lot about the divide in our portfolio if we think about our fund construction, or how we're looking at the world between consumer and B2B. What we think about is this thesis and the mechanics involved, for instance the role of building network driven businesses and the opportunity to leverage bottom up networks to create moats and scale and to broaden access by driving value and down costs systematically across categories we care about. Sometimes the right application when you pull the threads of that thesis is a consumer product or service, and sometimes it's the enabling infrastructure of them. But most of USV's investments had been one of those two things. They've either been the end application or the enabling infrastructure involved, but a common theme throughout our investments is how do you build important networks that can change industries, but rise outside of them. If you think about Journey Clinical, it's a network of therapists. They're stronger, and the more you add on to them, it's a bottom up growing network of acquiring the therapist, even though it interacts with the healthcare system and can change it. But it's growing this network outside of the infrastructure to then impact the existing structure. We really like that if you think across of our investments, and sometimes that turns out to be consumer, if you think about an Outschool in education, or a Duolingo, or a Twitter, and sometimes it turns out to be the enabling infrastructure or the B2B Marketplace application like Journey Clinical.Eric: What are your thoughts on AI in consumer?Rebecca: The piece of the AI craziness that I'm most excited about is the application layer. There's still a lot of kind of complexity and uncertainty on the foundational model and on the enabling infrastructure on where equity value aggregates — how much of the stack the models own, how defensible those models are, how that shakes out — but what I feel like we can have more conviction about is that it unleashes a wave of consumer innovation that's going to be really fun. The way this is gonna get utilized is by products that we want to use. I'm excited about unleashing this rejuvenated value around fun things to do, where the coolest thing about AI driven applications is they get better if people actually use them. So the strongest incentive of the team is to increase engagement and utility. The only way to do that is to combine utility with fun. There's gonna be so many things in the market that if things aren't fun to use, you'll go to another option. But the team has a huge incentive to get you to stick because that's how their product gets better. So if you think about something like Duolingo, which has been on this for a long time of leveraging machine learning and AI to create better consumer experiences — streaks, gamification, fun — infused with the utility of language learning is critical, because their product gets better if I use it. I'm really excited to see that apply to lots of different consumer applications. We've been talking a lot and everyone's been talking a lot about whether they're going to be moats. Is stickiness going to be possible? The barriers are so low. The moat is going to be fun and teams that can create rapid new fun things that keep you on the platform. We haven't seen that in a while. I'm excited about it. Get full access to Newcomer at www.newcomer.co/subscribe

Union Square Ventures has some of the best performing funds in the venture capital industry. As I've reported, USV-backer UTIMCO disclosed in a recent filing that USV had delivered the public investment fund an internal rate of return of 59%. And that number will likely go up over time. (For instance, USV portfolio company Casetext sold to Thomson Reuters for $650 million after the UTIMCO performance update.) I invited USV managing partner Rebecca Kaden onto the Newcomer podcast to talk about how USV consistently invests in unconventional companies. We started off our conversation talking about Journey Clinical, the psychedelics company, in which Kaden announced a Series A investment in January. We also discussed USV's $200 million climate fund strategy, her interest in the AI application layer, and how rising interest rates are effecting the venture capital asset class. Give it a listenHighlighted ExcerptsThe transcript has been edited for clarity.Eric: How do you repeatedly invest in weird things like psychedelics?Rebecca: This thesis around access to care, which has attracted so much capital — some of it ours and is proving to be a good category — has been where the market has gone, but it's actually only one piece of the puzzle. The way we get into things that are unusual is by having strong theses about where things are going versus being extremely opportunistic. Obviously, there's a balance. But that thesis thinking is important. A lot of thesis work on this category really led to the belief that access to care is only half the puzzle. The other is how is care itself going to evolve, and you start unraveling that thread: how is care itself evolving? The real biggest last evolution of care is SSRIs. Those are prescription drugs and have been very important to the treatment for mental health crises, but there's a lot of things they don't treat. They're not a one size fits all model. And they're basically all we got, right? The innovation has not had a lot of other layers, except for psychedelics. And so we became very interested in psychedelics as the next card to get turned over and the next option in needing a bucket of options to treat a crisis.Eric: There are pharmaceutical companies. If there's money to be made, shouldn't they be trying? What's happening that it feels like you need a real outsider thinking to bring ketamine, a drug that's legal, to people's lives that the medical system is unable or unwilling to do what's happening?Rebecca: Well, this isn't really unique to psychedelics or to mental health. Pharmaceutical companies make drugs, so the development of drugs goes with them, but the distribution and networks of access is outside of it. That's not particularly new or unique here. That's where business opportunity has been. So the idea is, when you talk about distribution and networks of access, that's often where these business opportunities lie. The development of drugs is kind of a different beast, which lies in the pharmaceuticals. Why is there a business opportunity with creating access? Because the same reason technology drives business opportunity into anything. Offline access is slower, it's more gated; it's more piecemeal. You have to be at the right doctor at the right time, you have to find it. By creating a network, you just allow anyone anywhere to find access and education at a faster speed and with much broader supply, which brings efficiency to the market.Eric: Do you think mushrooms are going to be on the table soon? Or how much was this a bet that the regulatory regime would change?Rebecca: I don't think mushrooms as we think about them in a recreational sense are just gonna get legalized, maybe they will, but that's a separate kind of thing. I think other forms of psychedelics in formats that are right for care are very much going to get legalized. And actually, as we did our research, to us that's a when not an if. When you dig into what's going on clinical trials and in the clinical world, in some ways that seems pretty easy to bet on that these will continue to happen. And if not exactly the form that we've outlined, rapid new forms of options for care for mental health diseases are going to get approved and released. They're going to need a network of education and distribution to go into the therapist network.I do think there's a regulatory risk here. There's some amount of regulatory risk on psychedelics. We have to be honest about it. But I actually think more about regulatory risk across broader online healthcare in general. We're at somewhat of a time of that whole market still getting worked out on not unique to mental health and not unique to psychedelics, but what you can prescribe online and to whom and to how and how to allow that really important access that we've come to rely on, but also do it in an appropriately controlled way.Eric: You come from a consumer focused firm. When you were interviewing with USV, was it clear that you were shifting away from consumer, and how have you thought about consumer professionally?Rebecca: We don't think a lot about the divide in our portfolio if we think about our fund construction, or how we're looking at the world between consumer and B2B. What we think about is this thesis and the mechanics involved, for instance the role of building network driven businesses and the opportunity to leverage bottom up networks to create moats and scale and to broaden access by driving value and down costs systematically across categories we care about. Sometimes the right application when you pull the threads of that thesis is a consumer product or service, and sometimes it's the enabling infrastructure of them. But most of USV's investments had been one of those two things. They've either been the end application or the enabling infrastructure involved, but a common theme throughout our investments is how do you build important networks that can change industries, but rise outside of them. If you think about Journey Clinical, it's a network of therapists. They're stronger, and the more you add on to them, it's a bottom up growing network of acquiring the therapist, even though it interacts with the healthcare system and can change it. But it's growing this network outside of the infrastructure to then impact the existing structure. We really like that if you think across of our investments, and sometimes that turns out to be consumer, if you think about an Outschool in education, or a Duolingo, or a Twitter, and sometimes it turns out to be the enabling infrastructure or the B2B Marketplace application like Journey Clinical.Eric: What are your thoughts on AI in consumer?Rebecca: The piece of the AI craziness that I'm most excited about is the application layer. There's still a lot of kind of complexity and uncertainty on the foundational model and on the enabling infrastructure on where equity value aggregates — how much of the stack the models own, how defensible those models are, how that shakes out — but what I feel like we can have more conviction about is that it unleashes a wave of consumer innovation that's going to be really fun. The way this is gonna get utilized is by products that we want to use. I'm excited about unleashing this rejuvenated value around fun things to do, where the coolest thing about AI driven applications is they get better if people actually use them. So the strongest incentive of the team is to increase engagement and utility. The only way to do that is to combine utility with fun. There's gonna be so many things in the market that if things aren't fun to use, you'll go to another option. But the team has a huge incentive to get you to stick because that's how their product gets better. So if you think about something like Duolingo, which has been on this for a long time of leveraging machine learning and AI to create better consumer experiences — streaks, gamification, fun — infused with the utility of language learning is critical, because their product gets better if I use it. I'm really excited to see that apply to lots of different consumer applications. We've been talking a lot and everyone's been talking a lot about whether they're going to be moats. Is stickiness going to be possible? The barriers are so low. The moat is going to be fun and teams that can create rapid new fun things that keep you on the platform. We haven't seen that in a while. I'm excited about it. Get full access to Newcomer at www.newcomer.co/subscribe

In this episode of the Practice of Therapy Podcast, host Gordon Brewer speaks with Jonathan Sabbagh, the Co-Founder, and CEO of Journey Clinical, about the revolutionary practice of using psychedelics in psychotherapy. Sabbagh shares his personal journey with post-traumatic stress disorder, anxiety, depression, and substance abuse and how he found relief through ayahuasca ceremonies. The conversation covers the history and research behind psychedelic therapy, the potential benefits and risks, and the future of integrating this practice into mainstream psychotherapy. Listen in to learn more about the transformative power of psychedelics in mental health treatment. Resources Mentioned In This Episode: Use the promo code "GORDON" to get 2 months of Therapy Notes free Private Practice Resources Join The PsychCraft Network Today! Launch Club The Practice of Therapy Community Focus Groups Jonathan Sabbagh on LinkedIn Journey Clinical Journey Clinical on Instagram Journey Clinical on Facebook

Jonathan is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to Psychedelic-Assisted Psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health, during which he personally experienced the transformative benefits of plant medicine and Ketamine-Assisted Psychotherapy (KAP). Jonathan's personal healing journey inspired him to begin formal clinical psychology training at The New School with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans living with depression and anxiety. Ultimately, Jonathan's personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale.In This EpisodeJonathan's website---What's new with The Trauma Therapist Project!The Trauma 5: gold nuggets from my 700+ interviewsThe Trauma Therapist Newsletter: a monthly resource of information and inspiration dedicated to trauma therapists.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5739761/advertisement

Lauren Taus has become quite a name in the psychedelic world. She is based in Los Angeles and is a licensed psychotherapist practicing Ketamine-assisted Psychotherapy (KAP) in Los Angeles, California. She integrates modern science and ancient wisdom to support personal transformation and much needed systemic change. She started “Inbodied Life” as a private psychotherapy practice, and it blossomed into a group practice that is also a platform for education through in-person, experiential trainings and retreats. Lauren sits also on the advisory board of Journey Clinical, an amazing psychedelic company based in NYC. To me, Lauren is one of the most interesting and also important people in the new psychedelic space. Her social media language is really speaking to me, since she has a great way to really get into the important questions around psychedelics: how does change actually look like? On a daily basis ? Why do we all need TO, which means “time out” and how psychedelics can support us with that. We address Laurens way from anorexia to healing and her way through the 12 steps program, we talk about her about her acid trip with her dad, a doctor, who now works with her And how it works, if your family is starting to look into psychedelics too. And of course we talk about how a psychedelic journey can bring fun to our lives. Something I feel we should also talk about more often and with Lauren this is possible. https://www.inbodiedlife.com/ https://www.journeyclinical.com/

Jonathan is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to Psychedelic-Assisted Psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health, during which he personally experienced the transformative benefits of plant medicine and Ketamine-Assisted Psychotherapy (KAP).  Jonathan's personal healing journey inspired him to begin formal clinical psychology training at The New School with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans living with depression and anxiety. Ultimately, Jonathan's personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale.  Learn more at www.JourneyClinical.com. This podcast is sponsored by PCSIntensive.com.

Show Summary:“I struggled with depression, anxiety, and substance abuse for most of my adult life. While traditional medication and ayahuasca helped, they failed to address all of my issues. Working with my therapist on ketamine-assisted psychotherapy mostly cured my PTSD.”Mental health is a major health concern in our world today, affecting 1 in 3 Americans who suffer from anxiety and depression, costing billions to the economy. Despite this pressing issue, mental health treatment has seen little change in the past 50 years. Patients receive disjointed care, with very limited interaction between their therapist and prescriber, resulting in inadequate treatment.But there is hope. Psychedelics are a game-changing development in mental health treatment, representing the first significant shift in this field in half a century.Jonathan Sabbagh, founder of Journey Clinical, knows firsthand the transformative benefits of plant medicine and Ketamine-Assisted Psychotherapy (KAP). After experiencing burnout and receiving a difficult PTSD diagnosis, he left the world of finance to focus on his mental health. Now, his mission is to help licensed mental health professionals deliver KAP on a larger scale.Join us in this episode as we explore the power of ketamine-assisted psychotherapy and psychedelics to revolutionize mental health treatment and offer much-needed support to those in need.Get a chance to win a free hair analysis from Provo Health by rating and leaving a review on Episode 63 of the Gutsy Health Podcast!Exceptional Highlights:Our lives are filled with various stressors that can take a toll on our mental health, making it crucial to seek support in times of crisis.Working with licensed mental health professionals trained in psychedelic-assisted therapy techniques such as CBT, harm reduction, and internal family systems can maximize the benefits of therapy.Effective psychedelic therapy is personalized, adapting to each patient's unique needs and experiences and empowering therapists to flexibly tailor their approach.Show Highlights: 05:08 - The pitfalls of diving into plant medicine or psychedelics without proper integration06:12 - Where can people find a therapist well-versed in psychedelics?06:54 - Why Jonathan left a successful finance career to pursue clinical psychology10:17 - The high cost of ignoring mental health 12:01 - The science behind ketamine-assisted psychotherapy (KAP) and how it functions as an antidepressant and dissociative anesthetic 16:42 - Exploring the benefits of a collaborative care model 19:05 - Journey Clinical's comprehensive approach to patient care, including preparation, dosing, and integration sessions26:05 - Jonathan's thoughts on unethical ketamine clinics that provide little support or follow-up for patients29:04 - Psychedelics lower your defense mechanisms and allow you to access deeper aspects of yourself30:15 - A brief introduction to internal family systems as a powerful therapeutic modality Important Links: Journey Clinical - https://www.journeyclinical.cIT'S GIVEAWAY TIME!

What happens when someone takes psychedelics + they experience painful memories or an overload of emotion + thoughts that they aren't equipped to handle by themselves? Lauren Taus, psychedelics assisted therapist, educator, advocate + founder of In-bodied life, joins me to dive into the relationship of psychedelics + trauma.  We get deep into some conversations about how psychedelics effect on our brain + body, which substances do we see as having a greater effect in working with trauma, what resources help support someone going through the healing work + much more.  In this episode, you'll hear: The clinical perspective on “trauma” - (What happens to a person after the happening) Layers + variations of forms of trauma that exist (Individual, generational + systemic) How psychedelics heal trauma stored in the body The impact of psychedelics on our nervous system Navigating “bad trips” + reframing to ultimately be generative for our growth The potency of preparation, supportive relationships + love How can someone support themselves when trauma spontaneously resurfaces? What does integration look like for individuals who experience new memories or traumas unlocked by the psychedelics?  Spiritually bypassing versus doing “the work” from a spiritual lens Honoring our traditions, ritual + ceremony from a place of authenticity  Navigating the cultural appropriation of indigenous practices + healing our ancestral shame Systemic trauma for the communities of color + how to become stronger allies THE SKINNY ON OUR SEXY GUESTS Lauren Taus is a psychedelic assisted therapist, educator and activist. Lauren is the Founder of INbodied Life, the co-Founder of the Psychedelic Coalition for Health, and a clinical advisor to Journey Clinical. Lauren runs a small group, psychotherapy practice in Los Angeles and leads immersive, experiential trainings for providers to learn psychedelic assisted therapy and integration. Lauren's deepest wish is to see wake people up to the wonders of life, and in doing so, create more systems change agents. Personal liberation supports the needed collective shift.  Training.INbodiedlife.com @lauren.taus  @inbodiedlifetherapy  @psychedeliccoalitionforhealth In just a couple of weeks I will be opening enrollment for my 4 week course for sex love psychedelics: ritual. Each class is LIVE as I guide you into a potent space for exploration + discovery. I will show you how you can transform sex from being something on your to-do list, to being an experience for expansion both in your sex + self. We get into the pleasure mechanics around sex, how you can incorporate more playfulness in the bedroom, harm reduction practices for psychedelics, sexual rituals, + sensual journeys in sex.  So if you've been feeling that your sex life could be so much more, I agree. and I want to share this with you. https://learn.sexloveyoga.com/SexLovePsychedelics --- Send in a voice message: https://podcasters.spotify.com/pod/show/sexlovepsychedelics/message

Jonathan Sabbagh is the co-founder and CEO of Journey Clinical, an integrative platform for medical professionals and mental health professionals to provide Ketamine-Assisted Psychotherapy with a team approach.  Find out more about Journey Clinical here https://www.journeyclinical.com/   Thanks for listening! Support us by becoming a subscriber to The Science of Psychotherapy Academy! Or you can simply buy us a cup of coffee! Please leave a review! (Reviews are fabulously important to us! On your podcast player you should find an option to review at the bottom of the main page for the podcast - after the list of available episodes) - Here's a link for iTunes. And please subscribe to our show!  You can also find our podcast at: The Science of Psychotherapy Podcast Homepage Or check us out on YouTube If you want more great science of Psychotherapy please visit our website thescienceofpsychotherapy.com Grab a copy of our latest book! The Practitioner's Guide to the Science of Psychotherapy

Encore Episode: Journey Clinical is on a mission to address the growing mental health crisis by unlocking access to legal, evidence-based Psychedelic-Assisted Psychotherapies (PAP) across the United States. Journey Clinical has built a turnkey telehealth platform that enables licensed mental health professionals to expand their practice, starting with Ketamine-Assisted Psychotherapy (KAP). Their novel decentralized clinic model provides member psychotherapists with unprecedented access to a KAP-trained medical team, as well as a robust care management platform designed to deliver personalized treatment plans for enhanced clinical outcomes. Over 1M+ licensed mental health professionals in the U.S. now have access to transformative psychedelic therapies to augment their practice and significantly improve patient outcomes. Jonathan Sabbagh is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform for licensed psychotherapists in the US to expand their practice with transformative psychedelic therapies. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health. During this period, he experienced firsthand the transformative benefits of psychedelic therapies, particularly plant medicine and Ketamine-Assisted Psychotherapy (KAP), which transformed his condition and inspired him to begin formal studies to become a clinical psychotherapist. Jonathan's personal breakthroughs with psychedelic-assisted psychotherapy, as well as his research studies at The New School motivated Jonathan to expand access to safe, effective psychedelic therapy for all. The result was the founding of Journey Clinical in 2020, a novel decentralized clinic mode for clinical psychotherapists that provides unprecedented access to KAP for their patients, giving over 1M+ licensed mental health professionals in the U.S. access to transformative psychedelic therapies to augment their practice and significantly improve patient lives.Jonathan and Dr. Hoye discusses his journey from the work of finance to the world of mental health and psychedelically assisted psychotherapy. This is an interesting voyage of transformation and healing, and we trust you will enjoy the conversation. To learn more and sign up for the Journey Clinical membership, please visit their website: www.JourneyClinical.com/Join-UsThe Psychology Talk Podcast is a unique conversation about psychology around the globe. Your host Dr. Scott Hoye talks about psychology with mental health practitioners and experts to keep you informed about issues and trends in the industry.https://psych-talk.com https://www.instagram.com/psychtalkpodcast/

If you have struggled with a serious depression or PTSD that does not resolve, even after trying everything, then you might have considered Psychedelic Assisted Psychotherapy.  This might involve a plant medicine like Ayahuasca, Psilocybin or maybe MDMA or Ketamine therapy.  Whichever approach you might have investigated you probably have noticed that there are huge costs, very little professional oversight, and possibly the requirement of travelling long distances to remote locations to acquire these treatments.  In other words, it is a treatment path that is not easily accessible, and for some, too scary to consider. Yet, there is gathering evidence that these approaches can be remarkably beneficial for those with treatment resistant mental health symptoms.  Jonathan Sabbagh is the founder and CEO of Journey Clinical.  The company was founded with his wife Myriam Barthes to address the needs of mental health consumers seeking unique treatments like Ketamine Assisted Psychotherapy within a safe and supervised environment, even with your own mental health practitioners.  Journey Clinical makes it possible for your practitioner to provide care before, during and after a KAP intervention. So what is Ketamine/Psychedelic Assisted Psychotherapy, what are the benefits and what can you expect if you chose this approach?  We will cover this and more in this radio show. If you are interested in more information about psychedelic assisted psychotherapy or want to find a trained therapist who is able to help, this show is for you. For more information about Journey Clinical:  Journey Clinical is a turnkey platform that makes it possible for licensed mental health professionals in private practice to deliver Ketamine-Assisted Psychotherapy (KAP) safely and effectively. They act as the therapist's in-house doctor, treatment partner and one-stop-shop for all KAP needs, providing KAP education, new patient referrals, peer consultation groups, marketing support, a robust library of resources and more.  https://www.journeyclinical.com/ Links & Resources: More about Journey Clinical: https://www.journeyclinical.com The Psychedelics Podcast: https://psychedelicstoday.com/2022/01/14/pt284/ How Psychedelics Changed my Life – Jonathan Sabbagh: https://www.independent.co.uk/voices/psychedelics-ketamine-psychotherapy-mental-health-b1928289.html

Myriam Barthes is the Co-founder & Chief Operating Officer at Journey Clinical, a telehealth platform that empowers licensed mental health professionals to offer psychedelic therapies in their own practice. She has over 10 years of experience as a management consultant in strategy & performance improvement at Ernst & Young and led the Impact team at an artificial intelligence startup in New York. She brings her operational expertise to serve the mission of Journey Clinical to expand affordable and equitable access to psychedelic therapies. In today's episode, Myriam describes the impact of ketamine on the mind and the body, and specifically how ketamine-assisted therapy compares to other psychedelic-assisted therapies. She goes on to discuss the importance of therapeutic alliance when approaching ketamine-assisted therapy and who the best candidates are for participating in this treatment. You can find out more about Journey Clinical and their work at www.journeyclinical.com

In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources.In this episode, we discuss:The journey from idea to 100+ therapist membersHow ketamine-assisted therapy works and the Journey Clinical's vision for the futureBalancing growth with protecting the relationship between patient and therapistCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Journey Clinical is on a mission to address the growing mental health crisis by unlocking access to legal, evidence-based Psychedelic-Assisted Psychotherapies (PAP) across the United States. Journey Clinical has built a turnkey telehealth platform that enables licensed mental health professionals to expand their practice, starting with Ketamine-Assisted Psychotherapy (KAP). Their novel decentralized clinic model provides member psychotherapists with unprecedented access to a KAP-trained medical team, as well as a robust care management platform designed to deliver personalized treatment plans for enhanced clinical outcomes. Over 1M+ licensed mental health professionals in the U.S. now have access to transformative psychedelic therapies to augment their practice and significantly improve patient outcomes. Jonathan Sabbagh is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform for licensed psychotherapists in the US to expand their practice with transformative psychedelic therapies. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health. During this period, he experienced firsthand the transformative benefits of psychedelic therapies, particularly plant medicine and Ketamine-Assisted Psychotherapy (KAP), which transformed his condition and inspired him to begin formal studies to become a clinical psychotherapist. Jonathan's personal breakthroughs with psychedelic-assisted psychotherapy, as well as his research studies at The New School motivated Jonathan to expand access to safe, effective psychedelic therapy for all. The result was the founding of Journey Clinical in 2020, a novel decentralized clinic mode for clinical psychotherapists that provides unprecedented access to KAP for their patients, giving over 1M+ licensed mental health professionals in the U.S. access to transformative psychedelic therapies to augment their practice and significantly improve patient lives.Jonathan and Dr. Hoye discusses his journey from the work of finance to the world of mental health and psychedelically assisted psychotherapy. This is an interesting voyage of transformation and healing, and we trust you will enjoy the conversation. To learn more and sign up for the Journey Clinical membership, please visit their website: www.JourneyClinical.com/Join-UsThe Psychology Talk Podcast is a unique conversation about psychology around the globe. Your host Dr. Scott Hoye talk about psychology with mental health practitioners and experts to keep you informed about issues and trends in the industry.https://psych-talk.com https://www.instagram.com/psychtalkpodcast/

In today's episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a $35M fund investing in psychedelic therapeutics. Palo Santo's portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.In this episode, we discuss:Tim's background in healthcare financeInvesting in classic psychedelic compounds vs. 2nd generation compoundsHallmarks of a good first meeting with a prospective investmentCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Welcome to season 2! Before we kick things off tomorrow with our first epic guest of the season, I wanted to bring you up to speed on my cancer journey, since I know so many of you care and have been wondering what's been going on during the show's hiatus! So join me for this quick episode for an update on my cancer journey, how I handle all the emotions as well as my mortality, and what's to come this season on The Reroute.   Follow me on TikTok: https://www.tiktok.com/@kasey.altman Follow me on IG: https://instagram.com/the.reroute    Want to collab? Email me at inquiries@the-reroute.com 

Journey Clinical, Jonathan Sabbagh and Myriam Barthes, is my guest today. VCs named their company one of the top 15 startups in the psychedelic field. Journey Clinical is a turnkey telehealth platform that enables licensed psychotherapists to include legal, evidence-based Psychedelic Assisted Psychotherapies (PAP) in their practice, starting with Ketamine-Assisted Psychotherapy (KAP). Their novel decentralized clinic model provides member psychotherapists with unprecedented access to a KAP-trained medical team, as well as a robust care management platform designed to deliver personalized treatment plans for enhanced clinical outcomes. Myriam describes the new clinical system as a triangle. In the first corner is the patient, in the second the journey clinical doctor, who is able to describe and administer the ketamine, in the third corner is the Journey Clinical member psychotherapist, vetted and often independent, who works with the patient after the treatment. Jonathan describes the company as a “one stop shop where all the required treatments get offered to you”. Which means, as a patient, you would not have to run around to physicians, psychiatrists or therapists,who would eventually contradict each other in their diagnosis or where at least one party would not be open to Ketamine Assisted psychotherapy. Journey Clinical is your new psychedelic in house doctor. Both founders have a background in finance and both have experienced how their lives have transformed with psychedelics. Jonathan, working in hedge funds, suffered from a heavy burn out and undiagnosed PTSD and addiction condition, he looked into an ayahuasca and MDMA experiences. Myriam is a firm believer in plant medicine, she had her own psychedelic healing story.We talk about, how therapists join the network, can access educational videos , then join peer consultation groups and then can start referring patients to the ketamine therapy, how Ketamine can support tapering off antidepressants that patients will still need to take, how repressed feelings and underlying topics of patients made their way to the top during COVID, which amplified peoples crisis and depression even more, how with a few Ketamine Assisted Psychotherapy sessions things start to bubble up, how the modern psychedelic clinic can look like very soon. https://www.businessinsider.com/list-top-psychedelics-startups-according-to-vcs-investors-2021 https://www.journeyclinical.com/

In this episode of the podcast, Joe interviews Jonathan Sabbagh, co-founder and CEO of Journey Clinical, which is a telehealth platform that helps approved therapists integrate KAP (and other modalities) into their practices. www.psychedelicstoday.com

Jonathan Sabbagh spent 20 years working in finance, where he built two businesses from the ground up. After experiencing an intense burnout, he was eventually diagnosed with PTSD. After therapy and medications failed to help him, Jonathan found relief in a series of traditional ayahuasca ceremonies and ketamine-assisted psychotherapy, experiences where he discovered he needed to lead a more integrated life and to be in service to others. Jonathan decided to quit finance and go back to school to study clinical psychology. As he set off on his journey, he felt the need to integrate his entrepreneurial skills into his new path of becoming a psychedelic therapist. He realized that he could apply his skills as a company builder to expand access to legal psychedelic treatments starting with ketamine. In 2020, Jonathan co-founded Journey Clinical to empower self-employed licensed clinicians and small practices to offer ketamine-assisted psychotherapy to their clients while remaining independent. Sign up for 10% off of Shrink Rap Radio CE credits at the Zur Institute